Improving cancer treatments
Clinical trials, also called research trials, are studies conducted to evaluate a new drug, a new combination of drugs, or new delivery protocols. These studies are designed to answer scientific questions and to find better ways to treat cancer patients.
Our Research Department offers the opportunity to participate in clinical trials that are appropriate for the patient’s disease or situation. Nebraska Hematology-Oncology is involved in clinical trials on an ongoing basis. This involvement keeps our physicians abreast of the latest developments in cancer drugs and treatment protocols. We encourage many of our patients to take advantage of new treatment protocols or participate in clinical trials which we offer.
Every patient must be evaluated before they can participate in a clinical trial. If you are interested in participating in a trial and your physician thinks you may be a good candidate for the study, everything will be explained to you in detail by your physician and research staff. The written consent form will assist you in making your decision of whether or not to participate. If you decide to participate, you must indicate that by signing the consent form prior to undergoing any procedures solely done for the study. You will be monitored closely throughout your care while on the study, both during and after treatment.
Many patients are concerned about the cost of treatment on clinical trials. Some drugs and tests may be provided free of charge by the study, while others may not. Items that are not provided by the study may be a part of any standard treatment plan and may be paid for by health insurance. If you have concerns, you can and should discuss any trial costs during the consent process, prior to making your decision to participate in the trial.
Nebraska Hematology-Oncology is currently participating in a variety of clinical trials including those listed below. Contact our Clinical Research Department for more information on these and other trials.
- HR-Positive, HER-2 Negative Advanced or Metastatic Breast Cancer
- ER-Positive, HER-2 Negative Early Breast Cancer
- First Line Treatment for Advanced Non-Small Cell Lung Cancer, Without Actionable Genomic Alterations